recast-jats-buildd8e1462159jitcJ Immunother CancerjitcJournal for ImmunoTherapy of CancerJ Immunother CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltdjitc-2020-00136110.1136/jitc-2020-00136133154150/jitc/8/2/e001361.atomClinical/translational cancer immunotherapyOpen accessClinical/Translational Cancer ImmunotherapySpecial collectionsJITCClinical/Translational Cancer ImmunotherapySpecial collectionsOpen accessOriginal researchIntegrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practicehttp://orcid.org/0000-0002-1209-5735CortelliniAlessio12TucciMarco34AdamoVincenzo5StucciLuigia Stefania3RussoAlessandro5TandaEnrica Teresa6SpagnoloFrancesco6RastelliFrancesca7BisonniRenato7SantiniDaniele8RussanoMarco8AnesiCecilia8GiustiRaffaele9FilettiMarco9MarchettiPaolo91011BotticelliAndrea10GelibterAlain11OcchipintiMario Alberto11MarconciniRiccardo12VitaleMaria Giuseppa13NicolardiLinda14ChiariRita14BareggiClaudia15NigroOlga16TuziAlessandro16De TursiMichele17PetragnaniNicola18PalaLaura19BracardaSergio20MacriniSerena20InnoAlessandro21ZorattoFederica22VeltriEnzo22Di CoccoBarbara22MallardoDomenico23VitaleMaria Grazia23http://orcid.org/0000-0002-3529-0103PinatoDavid James24PorzioGiampiero2FicorellaCorrado12http://orcid.org/0000-0002-8322-475XAsciertoPaolo Antonio23 Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bary, Italy National Cancer Research Center, Tumori Institute IRCCS Giovanni Paolo II, Bari, Italy Medical Oncology, Department of Human Pathology, A.O. Papardo, University of Messina, Messina, Italy IRCCS Ospedale Policlinico San Martino, Genova, Italy Medical Oncology, ASUR District Area 4 Fermo, Fermo, Italy Medical Oncology, Campus Bio-Medico University, Rome, Italy Medical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy Medical Oncology Unit B, Policlinico Umberto I, Sapienza University of Rome, Roma, Italy Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Medical Oncology, University Hospital Modena, Modena, Italy UOC Oncologia Padova Sud, Azienda ULSS 6 Euganea, Padova, Italy Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Milano, Italy Medical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy Department of Medical, Oral and Biotechnological Sciences, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Italy Department of Psychological, Health and Territorial Sciences, University G. D'Annunzio of Chieti and Pescara, Chieti, Italy Division of Medical Oncology for Melanoma, Sarcoma and Rare Tumors, IEO European Institute of Oncology IRCCS, Milan, Italy Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK Dr Alessio Cortellini; alessiocortellini@gmail.com 112020511202029620202962020511202082e00136128082020© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2020http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.Background

Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors.

Methods

We conducted a multicenter observational retrospective study aimed at evaluating the impact of concomitant medications on clinical outcomes, by weighing their associations with baseline clinical characteristics (including performance status, burden of disease and body mass index) and the underlying causes for their prescription. This analysis included consecutive stage IV patients with cancer, who underwent treatment with single agent antiprogrammed death-1/programmed death ligand-1 (PD-1/PD-L1) with standard doses and schedules at the medical oncology departments of 20 Italian institutions. Each medication taken at the immunotherapy initiation was screened and collected into key categories as follows: corticosteroids, antibiotics, gastric acid suppressants (including proton pump inhibitors - PPIs), statins and other lipid-lowering agents, aspirin, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), ACE inhibitors/Angiotensin II receptor blockers, calcium antagonists, β-blockers, metformin and other oral antidiabetics, opioids.

Results

From June 2014 to March 2020, 1012 patients were included in the analysis. Primary tumors were: non-small cell lung cancer (52.2%), melanoma (26%), renal cell carcinoma (18.3%) and others (3.6%). Baseline statins (HR 1.60 (95% CI 1.14 to 2.25), p=0.0064), aspirin (HR 1.47 (95% CI 1.04 to 2.08, p=0.0267) and β-blockers (HR 1.76 (95% CI 1.16 to 2.69), p=0.0080) were confirmed to be independently related to an increased objective response rate. Patients receiving cancer-related steroids (HR 1.72 (95% CI 1.43 to 2.07), p<0.0001), prophylactic systemic antibiotics (HR 1.85 (95% CI 1.23 to 2.78), p=0.0030), prophylactic gastric acid suppressants (HR 1.29 (95% CI 1.09 to 1.53), p=0.0021), PPIs (HR 1.26 (95% CI 1.07 to 1.48), p=0.0050), anticoagulants (HR 1.43 (95% CI: 1.16 to 1.77), p=0.0007) and opioids (HR 1.71 (95% CI 1.28 to 2.28), p=0.0002) were confirmed to have a significantly higher risk of disease progression. Patients receiving cancer-related steroids (HR 2.16 (95% CI 1.76 to 2.65), p<0.0001), prophylactic systemic antibiotics (HR 1.93 (95% CI 1.25 to 2.98), p=0.0030), prophylactic gastric acid suppressants (HR 1.29 (95% CI 1.06 to 1.57), p=0.0091), PPI (HR 1.26 (95% CI 1.04 to 1.52), p=0.0172), anticoagulants (HR 1.45 (95% CI 1.14 to 1.84), p=0.0024) and opioids (HR 1.53 (95% CI 1.11 to 2.11), p=0.0098) were confirmed to have a significantly higher risk of death.

Conclusion

We confirmed the association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors, which can be assumed to have immune-modulating detrimental effects.

immunotherapyspecial-featureunlockedspecial-propertycontains-inline-supplementary-materialIntroduction

Drug–drug interactions (DDIs) have traditionally played an important role in the safe and effective delivery of systemic anticancer therapy.1 Concomitant medications can alter efficacy and worsen toxicity from systemic therapies through pharmacodynamic (PK) and pharmacokinetic (PD) interactions, particularly due to interference with absorption, distribution, metabolism and elimination of drugs.1 The advent of immune checkpoint inhibitors (ICIs) has reignited the interest toward DDIs beyond traditional PK/PD considerations.2 ICIs exert their action mainly relying on the restoration/activation of T-cell responses against cancer, and therefore, might be altered by those factors which particularly affect the immune balance prior to the ICIs administration, such as disruption of the homeostatic balance within the gut microbiome3 and drug-induced immune suppression.4

Concomitant medications including steroids, proton pump inhibitors and systemic antibiotics have been postulated to exert immune-modulatory effects within the tumor microenviroment, thus affecting clinical outcomes from ICI therapy.2

However, while some degree of biological plausibility exists to justify an immune-mediated basis to the detrimental effect observed on response and survival from ICIs, the strength and reliability of the association has been largely derived from retrospective/post hoc analyzes and the dispute between causative instead of associative relationship has not been fully resolved.2 Given their immunosuppressive action, steroids were the first class of medications which was significantly related to worse clinical outcomes with cancer immunotherapy.5 Nevertheless, a significant association with worse outcome was later confirmed for baseline steroids administered for palliation of cancer-rleated symptoms but not for other indications including treatment of immune-related adverse events.6 7

In the case of systemic antibiotics, the evidence for a causative effect seems stronger and more plausible in view of their capacity to perturbate the gut microbiome, a renown determinant of response to ICIs.8–10 Nevertheless, the risk of collinearity with the underlying cause for the antibiotics prescription (eg, infections which might subtend to poorer clinical condition), has yet to be fully discriminated.

Proton pump inhibitors were associated to decreased progression-free survival (PFS) and overall survival (OS) in non-small-cell-lung-cancer (NSCLC) and melanoma patients receiving programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint inhibitors,9 11 while some studies investigated the impact of other concomitant medication, such as non-steroidal anti-inflammatory drugs (NSAIDs), metformin, aspirin, β-blockers and statins, without conclusive results.12 13

While a growing body of evidence underscores the importance of concomitant medications in affecting outcome from ICI, a key limitation affecting most of the published evidence is the lack of an integrated analysis of multiple classes of concomitant therapies. This is of particular importance to determine whether the influence on clinical outcomes might be driven by associative rather than causative links, especially given the high prevalence of polypharmacy in patients with cancer.14

Recently, we created a large multicenter, observational study of patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical practice, already subject of several analyzes,15–20 and we now gathered the baseline concomitant medication information for the same population, in order to evaluate their impact on clinical outcomes.

Materials and methodsStudy design

We conducted a real-world, multicenter, retrospective observational data collection aimed at evaluating the impact of concomitant medications at immunotherapy initiation on clinical outcomes, by weighing their associations with baseline clinical characteristics (including performance status, burden of disease and body mass index (BMI)) and the underlying indication for steroids, antibiotics and gastric acid suppressants prescription. This study included consecutive patients with confirmed diagnosis of stage IV solid cancer, who underwent treatment with single agent anti-PD-1/PD-L1 as first or subsequent line, with data availability regarding baseline concomitant medication. The data collection was further implemented and updated involving patients treated at the medical oncology departments of 20 Italian institutions (online supplemental table 1), between June 2014 and March 2020. Patients were treated according to the tumor type indication with pembrolizumab, nivolumab, atezolizumab and other PD-1/PD-L1 prescribed at doses and schedules indicated in the respective product SPCs.

SP110.1136/jitc-2020-001361.supp1

Clinical outcomes of interest included objective response rate (ORR), PFS and OS. Patients were assessed with radiological imaging in clinical practice, with a frequency ranging from 12 to 16 weeks, according to the monitoring requirements for high-cost drugs of the respective national drug regulatory agencies (the on-line monitoring dashboard of the ‘Agenzia Italiana del Farmaco’ requires a disease assessment at least every 16 weeks; available at: https://servizionline.aifa.gov.it/). RECIST (V. 1.1) criteria were used21 and a subsequent confirming imaging was recommended. However, treatment beyond disease progression was allowed when clinically indicated. ORR was defined as the portion of patients experiencing an objective response (complete or partial response) as best response to immunotherapy. PFS was defined as the time from treatment initiation to disease progression or death, whichever occurred first. OS was defined as the time from treatment initiation to death. For PFS as well as for OS, patients without events were considered as censored at the time of the last follow-up. Data cut-off period was May 2020.

Fixed multivariable regression models were used to estimate clinical outcomes according to each concomitant medication category following adjustment for preplanned adjusting covariates that might represent confounders.22–24 The key covariates were: primary tumor type (NSCLC, melanoma, renal cell carcinoma and others), age (<70 vs ≥70 years),25–28 sex (male vs female), Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) (0–1 vs ≥2), burden of disease (number of metastatic sites≤2 vs >2), treatment line (first vs non-first) and BMI. BMI was used given to its alleged role in affecting immunotherapy clinical outcomes15 16 and as a surrogate of cardiovascular/metabolic conditions which might have influenced the prescription of certain concomitant medications. Weight and height were obtained from patients’ medical records at the time of immunotherapy initiation. BMI was calculated using the formula of weight/height2 (kilograms per square meter) and categorized according to WHO categories: underweight, BMI <18.5 kg/m2; normal-weight, 18.5 kg/m2≤ BMI ≤24.9 kg/m2; overweight, 25 kg/m2≤ BMI ≤29.9 kg/m2; obese, BMI ≥30 kg/m2. In order to properly weighing the role of baseline concomitant medication, their association with ECOG-PS, burden of disease and with BMI were evaluated.

Concomitant medications

Information on prescribing of concomitant medications was gathered from patients’ clinical records. Each medication prescribed at the time of immunotherapy initiation was screened and categorized as follows:

Corticosteroids administration (dose ≥10 mg prednisone equivalent per day, with a minimum 24 hours of dosing) within the 30 days before immunotherapy initiation, classified according to their indication as: no (including those patients receiving <10 mg prednisone equivalent) versus cancer indications (administration for symptoms palliation, radiation therapy, central nervous system metastases) versus non-cancer indications (eg, other inflammation processes non related to cancer).

Systemic antibiotics within the 30 days before immunotherapy initiation, classified according to their indication as: no versus prophylaxis (eg, to prevent COPD exacerbation or diverticulitis prevention) versus infection (in case of a diagnosed infective disease).

Baseline gastric acid suppressant, classified according to their indication as: no vs gastritis/gastroesophageal reflux disease (GERD) versus prophylaxis (eg, to prevent gastritis due to other concomitant medication); no versus H2 Antagonists (such as ranitidine) vs proton pump inhibitors.

Baseline statins (yes vs no).

Other baseline lipid-lowering agents (fibrates, ezetimibe and similar) (yes vs no).

Baseline aspirin (considered as low-dose daily assumption of aspirin for cardiovascular prevention) (yes vs no).

Baseline anticoagulants (including new oral anticoagulants, low molecular weight heparin and cumarinic anticoagulant drugs) (yes vs no).

NSAIDs within the 30 days before treatment initiation, including COX-2 inhibitors (including both chronic and PRN administration) (yes vs no).

Baseline ACE inhibitors/angiotensin II receptor blockers (ARBs) (yes vs no), calcium antagonists (yes vs no), β-blockers (yes vs no).

Baseline metformin (yes vs no) and other oral antidiabetics (yes vs no).

Baseline opioids (yes vs no).

Statistical analysis

Baseline patient characteristics were reported with descriptive statistics. χ2 test was used for the univariate analysis of ORR. Logistic regression was used for the multivariate analysis of ORR and to compute the ORs with 95% CIs. Median PFS and median OS were evaluated using the Kaplan-Meier method. Median period of follow-up was calculated according to the reverse Kaplan-Meier method. Cox proportional hazards regression was used for the univariate analysis, for the fixed multivariate analysis of PFS and OS and to compute the HRs for disease progression and death with 95% CIs. The alpha level for all analyzes was set to p<0.05. χ2 test was also used to evaluate the associations between baseline concomitant medication and ECOG-PS (0–1 vs ≥2), burden of disease (number of metastatic sites≤2 vs>2) and BMI (underweight, normal-weight, overweight and obese). In order to properly evaluate the role of some baseline medications, a further analysis using the BMI as a continuous covariate was performed, through the one-way analysis of variance (ANOVA). All statistical analyzes were performed using MedCalc Statistical Software V.19.3.1 (MedCalc Software, Ostend, Belgium; https://www.medcalc.org; 2020).

ResultsPatients’ characteristics

In total, 1012 consecutive advanced cancer patients were evaluated. Patients characteristics are and baseline medication are summarized in table 1. The median age was 68.5 years (range: 21–92), male/female ratio was 647/365. Primary tumors were: NSCLC (52.2%), melanoma (26%), renal cell carcinoma (18.3%) and others (3.6%).

T1

Patients characteristics

N (%)1012
Age, (years)
 Median68.5
 Range21–91
 Elderly (≥70)452 (44.7)
Sex
 Male647 (63.9)
 Female365 (36.1)
ECOG PS
 0–1870 (86.0)
 ≥2142 (14.0)
Primary tumor
 NSCLC528 (52.2)
 Melanoma263 (26.0)
 Renal cell carcinoma185 (18.3)
 Others36 (3.6)
No of metastatic sites
 ≤2522 (51.6)
 >2490 (48.4)
Type of anti-PD-1/PD-L1 agent
 Pembrolizumab343 (33.9)
 Nivolumab613 (60.6)
 Atezolizumab32 (3.2)
 Others24 (2.3)
Treatment line of Immunotherapy
 First396 (39.1)
 Non-first616 (60.9)
BMI (kg/m2)
 Median (range)25.1 (13.5–50.8)
 Mean25.6
 Underweight38 (3.8)
 Normal weight460 (45.5)
 Overweight377 (37.3)
 Obese137 (13.5)
Baseline steroids
 Non-cancer related52 (5.1)
 Cancer related211 (20.8)
Systemic antibiotics
 Prophylaxis30 (3.0)
 Infection48 (4.7)
Gastric acid suppressant
 Prophylaxis100 (9.9)
 Gastritis/GERD447 (44.2)
Gastric acid suppressant
 H2 antagonists56 (5.5)
 Proton pump inhibitors491 (48.5)
Statins
 Yes196 (19.4)
Other lipid lowerings
 Yes48 (4.7)
Aspirin
 Yes189 (18.7)
Anticoagulants
 Yes145 (14.3)
NSAIDs
 Yes59 (5.8)
ACE inhibitors/ARBs
 Yes313 (30.9)
Calcium antagonist
 Yes140 (13.8)
Beta blockers*
 Yes114 (12.1)
Metformin
 Yes114 (11.3)
Other oral antidiabetics
 Yes46 (4.5)
Opioids†
 Yes68 (7.4)

*Available for 943 patients

†Available for 921 patients

ARBs, AngiotensinII receptor blockers; BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; GERD, gastroesophageal reflux disease; NSCLC, non-small cell lung cancer; PD-1/PD-L1, programmed death-1/programmed death ligand-1.

Efficacy analysis

The median follow-up was 24.2 months (95% CI 23.3 to 67.2); in the study population ORR was 37.6% (95% CI 33.8%% to 41.7) (361 responses out of 960 evaluable patients), while median PFS and median OS were 10.2 months (95% CI 9.2 to 11.4; 681 progression events) and 19.7 months (95% CI 17.5 to 24.6; 520 censored patients), respectively. Table 2 reports the univariate and multivariate analyzes of ORR. Compared with patients who did not received baseline steroids, patients receiving them for cancer-related symptoms were confirmed to have a significantly lower ORR compared with patients who did not receive baseline steroids (HR 0.55 (95% CI 0.38 to 0.81), p=0.0020), while not patients who received steroids for non-cancer indications. Also baseline statins (HR 1.60 (95% CI 1.14 to 2.25), p=0.0064), aspirin (HR 1.47 (95% CI 1.04 to 2.08), p=0.0267) and β-blockers (HR 1.76 (95% CI 1.16 to 2.69), p=0.0080) were confirmed to be independently related to an increased ORR. Table 3 summarizes the univariate and multivariate analyzes of PFS. Patients receiving cancer-related steroids (HR 1.72 (95% CI 1.43 to 2.07), p<0.0001), prophylactic systemic antibiotics (HR 1.85 (95% CI 1.23 to 2.78), p=0.0030), prophylactic gastric acid suppressants (HR 1.29 (95% CI 1.09 to 1.53), p=0.0021), proton pump inhibitors (HR 1.26 (95% CI 1.07 to 1.48), p=0.0050), anticoagulants (HR 1.43 (95% CI 1.15 to 1.76), p=0.0009) and opioids (HR 1.54 (95% CI 1.11 to 2.12), p=0.0083), were confirmed to have a significantly higher risk of disease progression. On the contrary, patients who assumed aspirin were confirmed to have a significantly lower risk of disease progression (HR 0.79 (95% CI 0.64 to 0.98), p=0.0318). Table 4 summarizes the univariate and multivariate analyzes of OS. Patients receiving cancer-related steroids (HR 2.16 (95% CI 1.76 to 2.65), p<0.0001), prophylactic systemic antibiotics (HR 1.93 (95% CI 1.25 to 2.98), p=0.0030), prophylactic gastric acid suppressants (HR 1.29 (95% CI 1.06 to 1.57), p=0.0091), proton pump inhibitors (HR 1.26 (95% CI 1.04 to 1.52), p=0.0172), anticoagulants (HR 1.45 (95% CI 1.14 to 1.84), p=0.0024) and opioids (HR 1.53 (95% CI 1.11 to 2.11), p=0.0098) were confirmed to have a significantly higher risk of death. Figures 1 and 2 report the Kaplan-Meier survival curves for PFS and OS according to baseline steroids, systemic antibiotics, gastric acid suppressants, anticoagulants and opioids.

F1

Kaplan-Meier survival estimates. Progression-free survival; (A) Steroids. No: 13.5 months (95% CI 10.8 to 15.4; 472 events); non-cancer indications: 10.0 months (95% CI 7.2 to 18.3; 36 events); cancer indications: 4.9 months (95% CI 3.6 to 6.5; 247 events); (B) Systemic antibiotics. No: 10.5 months (95% CI 9.2 to 11.9, 622 events); prophylaxis: 2.8 months (95% CI 2.1 to 6.7, 25 events); infections: 10.9 months (95% CI 6.4 to 37.5, 34 events); (C) Gastric acid suppressants. No: 13.5 months (95% CI 10.5 to 18.2, 288 events); gastritis/GERD: 11.2 months (95% CI 7.9 to 17.3, 60 events); prophylaxis: 8.2 months (95% CI 6.9 to 9.9, 333 events). Overall survival; (D) Steroids. No: 30.8 months (95% CI 24.4 to 36.3; 432 censored); non-cancer indications: 44.6 months (95% CI 12.0 to 44.6; 30 censored); cancer indications: 7.8 months (95% CI 5.4 to 9.8; 58 censored); (E) Systemic antibiotics. No: 22.8 months (95% CI 18.9 to 27.4, 494 censored); prophylaxis: 4.9 months (95% CI 3.5 to 11.0, 8 censored); infections: 15.2 months (95% CI 9.8 to 18.1, 18 censored); (F) Gastric acid suppressants. No: 29.4 months (95% CI 22.8 to 39.8, 266 censored); gastritis/GERD: 23.2 months (95% CI 13.4 to 30.8, 59 censored); prophylaxis: 14.8 months (95% CI 12.3 to 52.3, 195 censored). GERD, gastroesophageal reflux disease.

F2

Kaplan-Meier survival estimates. Progression-free survival; (A) Gastric acid suppressants. No: 13.5 months (95% CI 10.5 to 18.2, 288 events); H2 antagonists: 10.3 months (95% CI 3.8 to 13.9; 40 events); proton pump inhibitors: 8.4 months (95% CI 7.5 to 10.0; 353 events); (B) Anticoagulants. No: 10.9 months (95% CI 9.9 to 13.0, 573 events); yes: 6.3 months (95% CI 3.9 to 9.2, 108 events); (C) Opioids. No: 11.0 months (95% CI 10.0 to 13.5, 564 events); yes: 3.8 months (95% CI 2.9 to 6.4, 56 events). Overall survival (D) Gastric acid suppressants. No: 29.4 months (95% CI 22.8 to 39.8, 266 censored); H2 antagonists: 21.1 months (95% CI 6.1 to 25.0; 28 censored); proton pump inhibitors: 15.4 months (95% CI 12.5 to 18.1; 226 censored); (E) Anticoagulants. No: 23.9 months (95% CI 18.9 to 28.6, 460 censored); yes: 12.4 months (95% CI 7.8 to 15.1; 60 censored); (F) Opioids No: 23.2 months (95% CI 18.9 to 28.8, 452 censored); yes: 8.6 months (95% CI 4.7 to 12.7; 22 censored).

T2

Univariate and multivariate analyzes of ORR

Variable(Comparator)ORR
Univariarte analysisMultivariate analysis
Response/ratio—ORR (%) (95% CI)OR (95% CI); p valueaOR (95% CI); p value
Baseline steroids
 (No)293/715–41.0 (36.4 to 45.9)
 Non-cancer indications20/50–40.0 (24.4 to 61.7)0.96 (0.53 to 1.72); p=0.89171.18 (0.65 to 2.17); p=0.5836
 Cancer indications48/195–24.6 (18.1 to 32.6)0.47 (0.32 to 0.67); p<0.00010.55 (0.38 to 0.81); p=0.0020
Systemic antibiotics
 (No)340/883–38.5 (34.5 to 42.8)
 Prophylaxis5/29–17.2 (5.6 to 40.2)0.33 (0.12 to 0.88); p=0.02660.39 (0.14 to 1.05); p=0.0631
 Infection16/48–33.3 (19.1 to 54.1)0.79 (0.43 to 1.48); p=0.47350.89 (0.47 to 1.69); p=0.7314
Gastric acid suppressant
 (No)185/446–41.5 (35.7 to 47.9)
 Prophylaxis146/422–34.6 (29.2 to 40.7)0.74 (0.56 to 0.97); p=0.03420.85 (0.64 to 1.14); p=0.3057
 Gastritis/GERD30/92–32.6 (22.0 to 46.5)0.68 (0.42 to 1.09); p=0.11350.75 (0.46 to 1.24); p=0.2750
Gastric acid suppressant
 (No)185/446–41.5 (35.7 to 47.9)
 H2 antagonists19/51–37.3 (22.4 to 58.1)0.84 (0.46 to 1.53); p=0.57001.03 (0.55 to 1.93); p=0.9196
 Proton pump inhibitors157/463–33.9 (28.8 to 39.6)0.72 (0.55 to 0.95); p=0.02140.82 (0.62 to 1.09); p=0.1725
Statins
 (No)275/774–35.5 (31.4 to 39.9)1.56 (1.13 to 2.15); p=0.00701.60 (1.14 to 2.25); p=0.0064
 Yes86/186–46.2 (36.9 to 57.1)
Other lipid lowerings
 (No)345/915–37.7 (33.9 to 41.9)1.22 (0.66–2.24); p=0.51301.11 (0.59 to 2.09); 0.7271
 Yes19/45–42.2 (25.4 to 65.9)
Aspirin
 (No)281/780–36.0 (31.9 to 40.5)1.42 (1.02 to 1.97); p=0.03611.47 (1.04 to 2.08); 0.0267
 Yes80/180–44.4 (35.2 to 55.3)
Anticoagulants
 (No)319/826–38.6 (34.5 to 43.1)0.72 (0.49 to 1.07); p=0.10780.79 (0.53 to 1.19); 0.2774
 Yes42/134–31.3 (22.6 to 42.3)
NSAIDs
 (No)346/905–38.2 (34.3 to 42.4)0.61 (0.32 to 1.11); p=0.10640.64 (0.34 to 1.20); 0.1667
 Yes15/55–27.3 (15.2 to 44.9)
ACE inhibitors/ARBs
 (No)235/666–35.3 (30.9 to 40.1)1.37 (1.04 to 1.82); p=0.02581.26 (0.93 to 1.71); p=0.1241
 Yes126/294–42.9 (35.7 to 51.0)
Calcium antagonist
 (No)307/828–37.1 (33.0 to 41.5)1.17 (0.81 to 1.71); p=0.39901.07 (0.72 to 1.59); p=0.7188
 Yes54/132–40.9 (30.7 to 53.4)
β-blockers*
 (No)293/794–36.9 (32.8 to 41.4)1.71 (1.14 to 2.56); p=0.00921.76 (1.16 to 2.69); p=0.0080
 Yes54/108–50.0 (37.5 to 65.2)
Metformin
 (No)318/849–37.5 (33.4 to 41.8)1.06 (0.70 to 1.58); p=0.79301.02 (0.67 to 1.56); p=0.9081
 Yes43/111–38.7 (28.0 to 52.2)
Other oral antidiabetics
 (No)342/919–37.2 (33.3 to 41.4)1.45 (0.77 to 2.73); p=0.24021.34 (0.69 to 2.8); p=0.3808
 Yes19/41–46.3 (27.9 to 72.3)
Opioids†
 (No)317/822–38.6 (34.4 to 43.1)0.75 (0.43 to 1.33); p=0.33250.90 (0.49 to 1.63); p=0.7325
 Yes19/59–32.2 (19.4 to 50.3)
Primary tumor–
 (NSCLC)160/491–32.6 (27.8 to 38.1)
 Melanoma114/254–44.9 (37.0 to 53.9)1.68 (1.23 to 2.29); 0.0010
 Kidney74/180–41.1 (32.3 to 51.6)1.44 (1.02 to 2.05); 0.0406
 Others13/35–37.1 (19.7 to 63.5)1.22 (0.60 to 2.49); 0.5799
BMI–
 (Normal weight)12/36–33.3 (17.2 to 58.2)
 Underweight167/435–38.4 (32.8 to 44.7)0.83 (0.41 to 1.67); 0.6038
 Overweight128/352–36.3 (30.3 to 43.2)0.91 (0.68 to 1.22); 0.5226
 Obese54/136–39.7 (29.8 to 51.8)1.03 (0.69 to 1.53); 0.8709
Gender–
 (Female)128/348–36.8 (30.7 to 43.7)1.06 (0.81 to 1.39); p=0.6638
 Male233/612–38.1 (33.3 to 43.3)
Age–
 (Non-elderly)190/535–35.5 (30.6 to 40.9)1.22 (0.94 to 1.59); p=0.1338
 Elderly171/425–40.2 (34.5 to 46.7)
Treatment line–
 (First)181/373–48.5 (41.7 to 56.1)0.46 (0.39 to 0.61); p<0.0001
 Non-first180/587–30.7 (26.3 to 35.5)
No of metastatic sites–
 (≤2)203/503–40.4 (35.0 to 46.3)0.78 (0.60 to 1.01); p=0.0648
 >2158/457–34.6 (29.4 to 40.4)
ECOG PS–
 (0–1)322/828–38.9 (34.8 to 43.4)0.66 (0.44 to 0.98); p=0.0406
 ≥239/132–29.5 (21.0 to 40.4)

At the multivariate analysis, each drug category was adjusted for the preplanned key covariates separately.

*Available for 902 patients.

†Available for 881 patients.

ARBs, AngiotensinII receptor blockers; BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; GERD, gastroesophageal reflux disease; NSCLC, non-small cell lung cancer; ORR, objective response rate.

T3

Univariate and multivariate analyzes of PFS

Variable(Comparator)PFS
Univariate analysisMultivariate aanalysis
HR (95% CI); p valueaHR (95% CI); p value
Baseline steroids  
 (No)  
 Non-cancer indications1.08 (0.77 to 1.52); p=0.63700.96 (0.68 to 1.36); p=0.9681
 Cancer indications2.02 (1.69 to 2.40); p<0.00011.72 (1.43 to 2.07); p<0.0001
Systemic antibiotics  
 (No)  
 Prophylaxis2.27 (1.52 to 3.39); p=0.00011.85 (1.23 to 2.78); p=0.0030
 Infection1.12 (0.79 to 1.59); p=0.49530.99 (0.70 to 1.41); p=0.9772
Gastric acid suppressant
 (No)  
 Prophylaxis1.51 (1.29 to 1.76); p<0.00011.29 (1.09 to 1.53); p=0.0021
 Gastritis/GERD1.05 (0.79 to 1.39); p=0.74321.01 (0.75 to 1.33); p=0.9683
Gastric acid suppressant
 (No)  
 H2 antagonists1.33 (0.96 to 1.86); p=0.08431.05 (0.75 to 1.48); p=0.7435
 Proton pump inhibitors1.41 (1.21 to 1.65); p<0.00011.26 (1.07 to 1.48); p=0.0050
StatinsYes versus no0.88 (0.73 to 1.07); p=0.23290.87 (0.72 to 1.06); p=0.1944
Other lipid loweringsYes versus no1.06 (0.73 to 1.52); p=0.74981.21 (0.83 to 1.75); p=0.3061
AspirinYes versus no0.86 (0.71 to 1.06); p=0.16300.79 (0.64 to 0.98); p=0.0318
AnticoagulantsYes versus no1.49 (1.21 to 1.83); p=0.00011.43 (1.16 to 1.77); p=0.0007
NSAIDsYes versus no1.17 (0.86 to 1.59); p=0.31201.07 (0.78 to 1.47); p=0.6594
ACE inhibitors/ARBsYes versus no0.90 (0.76 to 1.07); p=0.23780.94 (0.79 to 1.12); p=0.5113
Calcium antagonistsYes versus no1.03 (0.83 to 1.28); p=0.75401.07 (0.86 to 1.34); p=0.5261
β-blockers*Yes versus no1.06 (0.84 to 1.35); p=0.61510.95 (0.75 to 1.22); p=0.7003
MetforminYes versus no1.16 (0.92 to 1.47); p=0.18681.13 (0.89 to 1.42); p=0.3059
Other oral anti-diabeticsYes versus no1.24 (0.89 to 1.75); p=0.19811.24 (0.88 to 1.74); p=0.2098
Opioids†Yes versus no2.05 (1.56 to 2.71); p<0.00011.71 (1.28 to 2.28); p=0.0002
Primary tumor  
 (NSCLC)  –
 Melanoma0.60 (0.49 to 0.72); p<0.0001
 Kidney0.75 (0.61 to 0.91); p=0.0050
 Others0.92 (0.59 to 1.44); p=0.7288
BMI  
 (Normal-weight)  –
 Underweight1.23 (0.83 to 1.83); p=0.2966
 Overweight0.95 (0.81 to 1.13); p=0.6090
 Obese0.80 (0.63 to 1.02); p=0.0761
GenderMale versus female1.11 (0.94 to 1.30); p=0.1920–
AgeElderly versus non-elderly0.98 (0.84 to 1.14); p=0.7948–
Treatment lineNon-first versus first1.45 (1.23 to 1.70); p<0.0001–
No of metastatic sites>2 vs ≤21.51 (1.29 to 1.75); p<0.0001–
ECOG PS≥2 vs 0–11.94 (1.58 to 2.38); p<0.0001–

At the multivariate analysis, each drug category was adjusted for the preplanned key covariates separately.

*Available for 943 patients.

†Available for 921 patients.

ARBs, AngiotensinII receptor blockers; BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; GERD, gastroesophageal reflux disease; NSCLC, non-small cell lung cancer; PFS, progression-free survival.

T4

Univariate and multivariate analyzes of OS

Variable(Comparator)Overall survival
Univariate analysisMultivariate analysis
HR (95% CI); p valueaHR (95% CI); p value
Baseline steroids  
 (No)  
 Non-cancer indications0.95 (0.62 to 1.47); p=0.84770.85 (0.54 to 1.31); p=0.4691
 Cancer indications2.76 (2.27 to 3.36); p<0.00012.16 (1.76 to 2.65); p<0.0001
Systemic antibiotics  
 (No)  
 Prophylaxis2.68 (1.74 to 4.13); p<0.00011.93 (1.25 to 2.98); p=0.0030
 Infection1.51 (1.04 to 2.18); p=0.03011.20 (0.82 to 1.75); p=0.3288
Gastricacid suppressant
 (No)  
 Prophylaxis1.57 (1.31 to 1.89); p<0.00011.29 (1.06 to 1.57); p=0.0091
 Gastritis/GERD1.07 (0.76 to 1.49); p=0.70660.98 (0.69 to 1.38); p=0.9309
Gastric acid suppressant 
 (No)  
 H2 antagonists1.30 (0.87 to 1.93); p=0.19191.04 (0.69 to 1.56); p=0.8444
 Proton pump inhibitors1.49 (1.23 to 1.79); p<0.00011.26 (1.04 to 1.52); p=0.0172
StatinsYes versus no0.81 (0.64 to 1.02); p=0.08100.79 (0.62 to 1.01); p=0.0622
Other lipid loweringsYes versus no1.01 (0.65 to 1.57); p=0.95341.31 (0.84 to 2.05); p=0.2275
AspirinYes versus no0.94 (0.75 to 1.19); p=0.65480.85 (0.67 to 1.07); p=0.1713
AnticoagulantsYes versus no1.61 (1.27 to 2.03); p=0.00011.45 (1.14 to 1.84); p=0.0024
NSAIDsYes versus no1.51 (1.07 to 2.11); p=0.01671.30 (0.92 to 1.83); p=0.1337
ACE inhibitors/ARBsYes versus no0.88 (0.72 to 1.07); p=0.22040.91 (0.74 to 1.11); p=0.3798
Calcium antagonistsYes versus no1.12 (0.87 to 1.44); p=0.36481.19 (0.92 to 1.54); p=0.1728
β-blockers*Yes versus no1.03 (0.77 to 1.36); p=0.85540.90 (0.68 to 1.20); p=0.4938
MetforminYes versus no1.31 (1.02 to 1.70); p=0.04131.24 (0.95 to 1.61); p=0.1040
Other oral antidiabeticsYes versus no1.34 (0.91 to 1.97); p=0.13041.26 (0.85 to 1.85); p=0.2475
Opioids†Yes versus no2.14 (1.58 to 2.91); p<0.00011.53 (1.11 to 2.11); p=0.0098
Primary tumor  
 (NSCLC)  –
 Melanoma0.45 (0.36 to 0.57); p<0.0001
 Kidney0.49 (0.38 to 0.63); p<0.0001
 Others0.60 (0.33 to 1.10); p=0.0992
BMI  
 (Normal weight)  –
 Underweight1.51 (0.98 to 2.32); p=0.0590
 Overweight0.97 (0.79 to 1.17); p=0.7592
 Obese0.78 (0.59 to 1.04); p=0.0981
GenderMale versus no0.97 (0.81 to 1.16); p=0.7499–
AgeElderly versus non-elderly1.11 (0.90 to 1.36); p=0.3138–
Treatment lineNon-first versus first1.49 (1.23 to 1.80); p<0.0001–
No of metastatic sites>2 vs ≤21.51 (1.26 to 1.79); p<0.0001–
ECOG PS≥2 vs 0–12.44 (1.96 to 3.05); p<0.0001–

At the multivariate analysis, each drug category was adjusted for the pre-planned key covariates separately.

*Available for 943 patients.

†Available for 921 patients.

ARBs, Angiotensin II receptor blockers; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group-Performance Status; GERD, gastroesophageal reflux disease; NSCLC, non-small cell lung cancer; PFS, progression-free survival.

Baseline associations

All the baseline associations are summarized in online supplemental table 5; the administration of baseline steroids (p<0.0001), systemic antibiotics (p=0.0001), gastric acid suppressant (both according to their indication (p<0.0001) and drug class (p=0.0002)), anticoagulants (p=0.0011), antidepressants (p=0.0002) and opioids (p=0.0123) was significantly associated to a poorer ECOG-PS. Similarly, the administration of baseline steroids (p=0.0014), gastric acid suppressant (both according to their indication (p<0.0001) and drug class (p<0.0001)), β-blockers (p=0.0166), and opioids (p=0.0014) was significantly associated to a higher burden of disease.

The administration of statins (p=0.005), anticoagulants (p=0.001), ACE inhibitors/ARBs (p=0.002), calcium antagonists (p=0.008), β-blockers (p=0.008), and other oral antidiabetics (p=0.036) was significantly associated to a higher BMI, while the administration of NSAIDs (p=0.003), and opioids (p=0.004) to a lower BMI at the ANOVA analysis. Using WHO categories for BMI, we confirmed the association with anticoagulants (p=0.0438), NSAIDs (0.0069) and opioids (p=0.0153).

Discussion

Identification of factors that prelude to immune-refractoriness is an area of high unmet need in cancer immunotherapy. A number of non-oncological medical therapies have been postulated to render the tumor microenviroment more tolerogenic, therefore exerting detrimental effects on depth, duration of response and survival of patients treated with ICI.2 Our purpose was to provide a more comprehensive analysis with a large population of patients with different malignancies receiving PD-1/PD-L1 inhibitors, in order to gain reliable results about the putative immune-modulating effects of concomitant medication most usually taken by patients with cancer.

We produce important confirmatory evidence regarding the association between exposure to steroids, systemic antibiotics and proton pump inhibitors and worse outcomes from ICI. In addition, we provide novel evidence for a shorter survival in patients on anticoagulants and opioids at ICIs initiation, a finding that was not previously reported in large populations. Similarly, a significant association between improved ORR/PFS and baseline aspirin, and between improved ORR and statins and β-blockers, had never been reported in the context of cancer patients receiving PD-1/PD-L1 inhibitors.

Intriguingly, among the baseline medication which resulted to be significantly related to clinical outcomes in our study population, the common thread might be somehow considered the immune modulating effects, particularly exerted through the modifying pressure on the gut-microbiome.

Steroids were the only baseline medication concordantly related to ORR, PFS and OS in our study population. Glucocorticoids can affect the gut microbiome, the intestinal mucosa and synthesis/secretion of mucins.29–31 Nevertheless, we have to consider the possible associative (and not causative) effect played by the significant relation between steroids assumption and poorer PS/higher burden of disease. In fact, patients receiving baseline steroids for symptoms palliation were confirmed to have significantly worse ORR, PFS and OS, compared with patients who did not received steroids, while not patients who received steroids for non-cancer indications, similarly to what reported by Ricciuti et al.6

It is also well known that antibiotics might affect immunity by inducing gut microbiome alterations.32 In our study, only systemic antibiotics administered for prophylaxis were confirmed to be significantly related to shortened PFS and OS at the multivariate analysis, while not antibiotics administered to treat active infections. Interestingly, it was further revealed that antibiotics administered prior of the immunotherapy initiation was confirmed to be related to worse outcomes, while not those administered concurrently,10 supporting the hypothesis that the underlying modulating effects on the gut microbiome can affect the immunotherapy clinical outcomes only when the modifying pressure is exerted on the prior immune-balance, and not during the treatment. From this perspective, antibiotics administered for prophylactic indications might exert the same negative effect of those administered to treat active infections. However, we have to consider that patients receiving antibiotics have poorer clinical conditions overall and looking at the table 5 we can noticed that those on prophylactic antibiotics had the highest percentage of ECOG-PS ≥2 patients.

T5

Summary of the associations between each drug category and ECOG-PS, burden of disease and BMI

ECOG-PS (%)χ2 No of metastatic sites (%)χ2 BMIχ2 BMI (continuous)One-way ANOVA
0–1≥2P value≤2>2P value≤18.518.5–2525–30≥30P valueMean (SD)F-ratio; P value
Baseline steroids      F(21 005)=3.16; p=0.043
 (No)671 (89.6)78 (10.4) p<0.0001 410 (54.7)339 (45.3) p=0.0014 27 (3.6)330 (44.1)288 (38.5)104 (13.9) p=0.3548 25.8(4.5)
 Non-cancer indications43 (82.7)9 (17.3)18 (34.6)34 (65.4)1 (1.9)22 (42.3)19 (36.5)10 (19.2)26.9(4.3)
 Cancer indications156 (73.9)55 (26.1)94 (44.5)117 (55.5)10 (4.7)108 (51.2)70 (33.2)23 (10.9)24.9(4.4)
Systemic antibiotics      F(21 005)=0.94; p=0.388
 (No)815 (87.3)78 (10.4) p=0.0001 482 (51.6)452 (48.4) p=0.9826 37 (4.0)416 (44.5)352 (37.7)129 (13.8) p=0.3921 25.7(4.5)
 Prophylaxis19 (63.3)9 (17.3)15 (50.0)15 (50.0)1 (3.3)16 (53.3)11 (36.7)2 (6.7)24.5(3.5)
 Infection36 (75.0)55 (26.1)25 (52.1)23 (47.9)–28 (58.3)14 (29.2)6 (12.5)25.5(3.4)
Gastric acid suppressant      F(21 005)=2.66; p=0.070
 (No)422 (90.8)43 (9.2) p<0.0001 275 (59.1)190 (40.9) p<0.0001 21 (4.5)211 (45.4)174 (37.4)59 (12.7) p=0.7860 25.5(4.5)
 Prophylaxis93 (93.0)7 (7.0)189 (42.3)258 (57.7)13 (2.9)201 (45.0)166 (37.1)67 (15.0)24.9(4.3)
 Gastritis/GERD355 (79.4)92 (20.6)58 (58.0)42 (42.0)4 (4.0)48 (48.0)37 (37.0)11 (11.0)25.9(4.5)
Gastric acid suppressant      F(21 005)=0.77; p=0.462
 (No)422 (90.8)43 (9.2)p<0.0001  275 (59.1)190 (40.9) p<0.0001 21 (4.5)211 (45.4)174 (37.4)59 (12.7) p=0.7860 25.5(4.5)
 H2 antagonists44 (78.6)7 (7.0)189 (42.3)258 (57.7)13 (2.9)201 (45.0)166 (37.1)67 (15.0)25.3(3.4)
 Proton pump inhibitors404 (82.392 (20.6)58 (58.0)42 (42.0)4 (4.0)48 (48.0)37 (37.0)11 (11.0)25.8(4.6)
Statins      F(11 006)=7.87; p=0.005
 (No)697 (85.4)119 (14.6)p=0.3027 415 (50.9)401 (49.1)p=0.3478 36 (4.4)377 (46.2)296 (36.3)107 (13.1)p=0.0718 25.4(4.4)
 Yes173 (88.3)23 (11.7)107 (54.6)89 (45.4)2 (1.0)83 (42.3)81 (41.3)30 (15.3)26.4(4.7)
Other lipid lowerings      F(11 006)=3.81; p=0.051
 (No)830 (86.1)134 (13.9)p=0.5904 491 (50.9)473 (49.1)p=0.0649 36 (3.7)447 (46.4)353 (36.6)128 (13.3)p=0.0727 25.5(4.5)
 Yes40 (83.3)8 (16.7)31 (64.6)17 (35.4)2 (4.2)13 (27.1)24 (50.0)9 (18.8)26.9(4.2)
Aspirin      F(11 006)=0.47; p=0.493
 (No)710 (86.3)113 (13.7)p=0.5648 421 (51.2)402 (48.8)p=0.5710 35 (4.3)371 (45.1)305 (37.1)112 (13.6)p=0.3756 25.6(4.5)
 Yes160 (84.7)29 (15.3)101 (53.4)88 (46.6)3 (1.6)89 (47.1)72 (38.1)25 (13.2)25.8(4.1)
Anticoagulants      F(11 006)=11.44; p=0.001
 (No)758 (87.4)109 (12.6)p=0.0011 444 (51.2)423 (48.8)p=0.5649 36 (4.2)405 (46.7)314 (36.2)112 (12.9)p=0.0438 25.4(4.5)
 Yes112 (77.2)33 (22.8)78 (53.8)67 (46.2)2 (1.4)55 (37.9)63 (43.4)25 (17.2)26.8(4.6)
NSAIDs      F(11 006)=9.03; p=0.003
 (No)819 (85.9)134 (14.1)p=0.9143 490 (51.4)463 (48.6)p=0.6741 33 (3.5)424 (44.5)364 (38.2)132 (13.9)p=0.0069 25.7(4.4)
 Yes51 (86.4)8 (13.6)32 (54.2)27 (45.8)5 (8.5)36 (61.0)13 (22.0)5 (8.5)23.9(4.8)
ACE inhibitors/ARBs      F(11 006)=9.42; p=0.002
 (No)604 (45.9)95 (13.6)p=0.5465 352 (50.4)347 (49.6)p=0.2448 30 (4.3)333 (47.6)247 (35.3)89 (12.7) 25.3(4.3)
 Yes266 (54.1)47 (15.0)170 (54.3)143 (45.7)8 (2.6)127 (40.6)130 (41.5)48 (15.3) 26.3(4.7)
Calcium antagonist      F(11 006)=7.01; p=0.008
 (No)755 (86.6.9)117 (13.4)p=0.1605 446 (51.5)426 (48.9)p=0.4905 36 (4.1)401 (46.0)322 (36.9)113 (13.0)p=0.2146 25.5(4.4)
 Yes115 (82.1)25 (17.9)76 (54.3)64 (45.7)2 (1.4)59 (42.1)55 (39.3)24 (17.1)26.6(4.9)
β-blockers*      F(1937)=9.96; p=0.008
 (No)713 (86.0)116 (14.0)p=0.3118 441 (53.2)388 (46.8)p=0.0166 35 4.2)388 (46.8)303 (36.6)103 (12.4)p=0.1493 25.4(4.5)
 Yes94 (82.5)20 (17.5)47 (41.2)67 (58.8)1 (0.9)47 (41.2)48 (42.2)18 (15.8)26.6(4.1)
Metformin      F(11 006)=0.37; p=0.542
 (No)777 (86.5)121 (13.5)p=0.1522 456 (50.8)442 (49.2)p=0.1524 36 (4.0)407 (45.3)331 (36.9)124 (13.8)p=0.5393 25.6(4.5)
 Yes93 (81.6)21 (18.4)66 (57.9)48 (42.1)2 (1.8)53 (46.5)46 (40.4)13 (11.4)25.9(4.6)
Other oral antidiabetics      F(11 006)=4.42; p=0.036
 (No)831 (86.0)135 (14.0)p=0.8127 495 (51.2)471 (48.8)p=0.3233 38 (3.9)443 (45.9)356 (36.9)129 (13.4)p=0.2597 25.6(4.5)
 Yes39 (84.8)7 (15.2)27 (58.7)19 (41.3)–17 (37.0)21 (45.7)8 (17.4)26.9(4.8)
Opioids†      F(1915)=8.26; p=0.004
 (No)735 (86.2)118 (13.8)p=0.0123 448 (52.5)405 (47.5)p=0.0014 29 (3.4)389 (45.6)320 (37.5)115 (13.5)p=0.0153 25.6(4.4)
 Yes51 (75.0)17 (25.0)22 (32.4)46 (67.6)6 (8.8)37 (54.4)22 (32.4)3 (4.4)24.0(4.1)

ANOVA, analysis of variance; ARBs, Angiotensin II receptor blockers; BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; GERD, gastroesophageal reflux disease.

Previous studies investigated the role of proton pump inhibitors exclusively,9 11 while this is the first analysis which evaluated the role of gastric acid suppressants overall. Proton pump inhibitors could negatively affect the gut microbiome due to both the changes of the gastric pH and to bacterial species selections,33 34 but also H2 antagonists are known to have modifying gut microbiome functions and to induce intestinal barrier dysfunctions.35 36 Curiously, proton pump inhibitors administration was confirmed to be associated to shortened PFS and OS, but not H2 antagonists and patients receiving gastric acid suppressants for prophylactic purpose experienced significantly shorter PFS and OS, while patients who received these agents to treat gastritis/GERD achieved similar outcomes to patients who did not receive them. In this case, the highest percentage of patients with ECOG-PS ≥2 is among the patients with gastritis/GERD and among the patients on H2 antagonists, but to proper weigh our results, we must take into account the significant association between baseline gastric acid suppressants and burden of disease (online supplemental table 3). Therefore, we are not able to recommend H2 antagonists prescription instead of proton pump inhibitors for patients with cancer who are in need of a gastric acid suppressant treatment and are going to receive a PD-1/PD-L1 checkpoint inhibitor, even more considering the recent alerts from drug regulatory agencies regarding the possible contamination with N-nitrosodimethylamine of some of these agents.37 38

Anticoagulants have been assumed to modulate the immune balance, affecting the antibacterial innate immune response,39 while chronic opioid dosing has been already associated to shift of the gut microbiome and intestinal barrier dysfunction.40–43 Nevertheless, it should be considered that patients requiring anticoagulation therapy and opioids are often frailer than patients who do not: a point that should be emphasized when evaluating PFS and OS where poorer PS and higher disease burden may confound the analyzes.

The relationship between aspirin and cancer prevention/progression have been historically known,44 45 but in the setting of immunotherapy of cancer, few studies have been published. Wang et al 12 evaluated a cohort of 330 melanoma patients receiving PD-1 inhibitors, without reporting any association between ORR, PFS, OS and NSAIDs use (including aspirin). Even if (cyclooxygenase) COX-2 expression was known to be positively associated with PD-L1 tumor expression,46 we did not find associations between baseline NSAIDs (excluding aspirin) and immunotherapy clinical outcomes, but the significant association between improved ORR and baseline aspirin, allows to speculate about the possible synergistic effects of COX inhibition in antitumor immunity.47 To our knowledge, the association between statins administration and improved clinical outcomes of patients with cancer receiving ICIs have never been described, however, it is well known that cholesterol metabolism plays a role in CD8+T cell function and might be modulated in order to enhance antitumor immunity.48–51 β-blockers have already been known to improve recurrence-free survival in patients with radically resected melanoma and to have synergistic effects with immunotherapy in mice models.52 53 In our cohort baseline β-blockers are significantly associated to improved ORR, while in the study of Wang et al no significant associations were found.12 Intriguingly, the inhibition of β-adrenoceptors in the intestinal mucosa and gut lymphatic tissue has been linked with changes in type and virulence of the intestinal microbiome and to reduced bacterial translocation trough the intestinal barrier.54 Finally, to properly weighing the ORR analysis results, we have to consider the significant association between β-blockers and low burden of disease and between β-blockers, aspirin, lipid-lowering agents and higher baseline BMI. However, contrary to what we previously reported,15 16 BMI was not significantly associated to improved outcomes in this population, even though a trend toward better ORR, PFS and OS for increased BMI levels was found. Considering that the most robust evidence of an association between improved outcomes and obesity came from NSCLC,55 this finding might be related to the internal distribution of the study population, which after the update and the addition of data from some new institutions passed form 65.1% and 18.7% of NSCLC and melanoma patients to 52.2% and 26%, respectively.

Despite the suggestion that metformin administration might exert a synergistic antitumor role with ICIs,2 56 we did not find any significant association between ORR, PFS, OS and baseline metformin, in keeping with previously published evidence.12

Beyond the dispute between association and causation, we have to consider that there are some other potential mechanisms by which concomitant medications could affect clinical outcomes during immunotherapy, in addition to gut microbiome alteration. It is well known that corticosteroids can exert immune-suppressive effects through several mechanisms, such as activation of glucocorticoid response elements with the inhibition of interleukin 1 (IL-1) and IL-6 transcription,57 58 induction of T-cell suppression and diminishing naïve T cell proliferation.59 Gastric acid suppressants can cause immune-suppressive effects through the inhibition of adhesion molecules of inflammatory cells and affecting cytokines secretion.60 Aspirin can exert several effects on both innate and adaptive immune responses. It can modulate proliferation/maturation of immune cells, regulate the cytokine production, and induce the lipoxin-driven immune counter-regulation. Nevertheless, aspirin can also have the immune suppressive ability of inducing tolerogenic dendritic cells, therefore expanding Treg cells.61

Our study acknowledges a number of limitations, including the retrospective design and the lack of central radiology review. The heterogeneity of tumor types evaluated might had affected the analysis even if we included the primary tumor in the preplanned fixed multivariate model. We have to also consider the small sample size of some subgroups as patients receiving steroids for non-cancer indication, gastric acid suppressants to treat gastritis/GERD and receiving H2 antagonists. Moreover, we are planning to investigate the possible detrimental effect on immunotherapy clinical outcomes of specific polypharmacy patterns. To confirm our results, interactions between concomitant baseline medications and immunotherapy clinical outcomes should be assessed prospectively.

Conclusion

This is the largest study to provide a broad, integrated analysis of multiple concomitant medications as determinants of response and survival to immunotherapy in patients with solid tumors. While unable to discriminate between a mechanistic and an associative effect, our study strengthens the knowledge around the association between baseline steroids administered for cancer-related indications, systemic antibiotics, proton pump inhibitors and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors, which can be assumed to have immune-modulating detrimental effects. To correctly weight the association between anticoagulants/opioids and worse PFS/OS we must consider their statistical association with poorer PS/higher burden of disease, while the significant association between the administration of aspirin, β-blockers, statins and improved ORR deserves further investigations.

@Al3ssandroRusso

All authors contributed to the publication according to the ICMJE guidelines for the authorship. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

This work was supported by the Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO). DP is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and from the NIHR Imperial Biomedical Research Center (BRC) ITMAT Push for Impact Scheme 2019 and acknowledges infrastructural support by the Cancer Research UK Imperial Center and the Imperial Experimental Cancer Medicine Center (ECMC).

AC received speaker fees and grant consultancies from Roche, MSD, BMS, AstraZeneca, Novartis, Astellas. RG received speaker fees and grant consultancies from AstraZeneca and Roche. MGV received speaker fees, grant consultancies and travel support from BMS, Ipsen, Novartis, Pfizer, Astellas, Jansen and Pierre-Fabre. AR received grant consultancies from AstraZeneca and MSD. RM received grant consultancies from Pierre-Fabre, MSD, Incyte, BMS, and Roche. FS received speaker fees and grant consultancies from Roche, Novartis, BMS, MSD, Pierre-Fabre, Sanofi, Merck and Sunpharma. DP received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. PAA received speaker fees and grant consultancies from BMS, Roche-Genentech, MSD, Dohme, Array, Novartis, Merck-Serono, Pierre-Fabre, Incyte, New Link Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim; he also received research funds from BMS, Roche-Genentech, Array.

Not required.

All patients alive at the time of data collection provided an informed consent for the present retrospective analysis. The procedures followed were in accordance with the precepts of Good Clinical Practice and the declaration of Helsinki. The study was approved by the respective local ethical committees on human experimentation of each institution, after previous approval by the coordinating center (University of L’Aquila, Internal Review Board protocol number 32865, approved on July 24 2018).

Not commissioned; externally peer reviewed.

The datasets used during the present study are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

References Scripture CD , Figg WD . Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546–58.doi:10.1038/nrc1887 http://www.ncbi.nlm.nih.gov/pubmed/16794637 [published correction appears in Nat Rev Cancer. 2006 Sep;6(9):741] Hussain N , Naeem M , Pinato DJ . Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? Hum Vaccin Immunother 2020:1–7.doi:10.1080/21645515.2020.1769398 http://www.ncbi.nlm.nih.gov/pubmed/32574106 Gopalakrishnan V , Helmink BA , Spencer CN , et al . The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 2018;33:570–80.doi:10.1016/j.ccell.2018.03.015 http://www.ncbi.nlm.nih.gov/pubmed/29634945 Malmberg K-J . Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 2004;53:879–92.doi:10.1007/s00262-004-0577-x http://www.ncbi.nlm.nih.gov/pubmed/15338206 Arbour KC , Mezquita L , Long N , et al . Impact of baseline steroids on efficacy of programmed cell death-1 and programmed Death-Ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018;36:2872–8.doi:10.1200/JCO.2018.79.0006 http://www.ncbi.nlm.nih.gov/pubmed/30125216 Ricciuti B , Dahlberg SE , Adeni A , et al . Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus Nonpalliative indications. J Clin Oncol 2019;37:1927–34.doi:10.1200/JCO.19.00189 http://www.ncbi.nlm.nih.gov/pubmed/31206316 Petrelli F , Signorelli D , Ghidini M , et al . Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 2020;12:546. doi:10.3390/cancers12030546 http://www.ncbi.nlm.nih.gov/pubmed/32120803 Derosa L , Hellmann MD , Spaziano M , et al . Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 2018;29:1437–44.doi:10.1093/annonc/mdy103 http://www.ncbi.nlm.nih.gov/pubmed/29617710 Chalabi M , Cardona A , Nagarkar DR , et al . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the oak and poplar trials. Ann Oncol 2020;31:525–31.doi:10.1016/j.annonc.2020.01.006 http://www.ncbi.nlm.nih.gov/pubmed/32115349 Pinato DJ , Howlett S , Ottaviani D , et al . Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol 2019;5:1774–8.doi:10.1001/jamaoncol.2019.2785 http://www.ncbi.nlm.nih.gov/pubmed/31513236 Homicsko K , Richtig G , Tuchmann F , et al . Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients. Ann Oncol 2018;29:x40.doi:10.1093/annonc/mdy511.001 Wang DY , McQuade JL , Rai RR , et al . The impact of nonsteroidal anti-inflammatory drugs, beta blockers, and metformin on the efficacy of anti-PD-1 therapy in advanced melanoma. Oncologist 2020;25:e602–5.doi:10.1634/theoncologist.2019-0518 http://www.ncbi.nlm.nih.gov/pubmed/32162820 Gandhi S , Pandey M , Ammannagari N , et al . Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors. Immunotherapy 2020;12:141–9.doi:10.2217/imt-2019-0064 http://www.ncbi.nlm.nih.gov/pubmed/32064978 Hakozaki T , Hosomi Y , Shimizu A , et al . Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy. J Cancer Res Clin Oncol 2020;146:2659–68.doi:10.1007/s00432-020-03252-4 http://www.ncbi.nlm.nih.gov/pubmed/32462298 Cortellini A , Bersanelli M , Buti S , et al . A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 2019;7:57. doi:10.1186/s40425-019-0527-y http://www.ncbi.nlm.nih.gov/pubmed/30813970 Cortellini A , Bersanelli M , Santini D , et al . Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur J Cancer 2020;128:17–26.doi:10.1016/j.ejca.2019.12.031 http://www.ncbi.nlm.nih.gov/pubmed/32109847 Cortellini A , Buti S , Bersanelli M , et al . Evaluating the role of family history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncoimmunology 2020;9:1710389. doi:10.1080/2162402X.2019.1710389 http://www.ncbi.nlm.nih.gov/pubmed/32002308 Cortellini A , Vitale MG , De Galitiis F , et al . Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. J Transl Med 2019;17:376. doi:10.1186/s12967-019-02132-x http://www.ncbi.nlm.nih.gov/pubmed/31730009 Cortellini A , Buti S , Santini D , et al . Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with Anti-Programmed death-1 immunotherapy: a real-world transverse study. Oncologist 2019;24:e327–37.doi:10.1634/theoncologist.2018-0618 http://www.ncbi.nlm.nih.gov/pubmed/30796151 Cortellini A , Chiari R , Ricciuti B , et al . Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer 2019;20:237–47.doi:10.1016/j.cllc.2019.02.006 http://www.ncbi.nlm.nih.gov/pubmed/30885550 Eisenhauer EA , Therasse P , Bogaerts J , et al . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.doi:10.1016/j.ejca.2008.10.026 http://www.ncbi.nlm.nih.gov/pubmed/19097774 Woolley KK . How variables uncorrelated with the dependent variable can actually make excellent predictors: the important suppressor variable case. Southwest educational research association annual meeting proceedings, 1997. Available: https://eric.ed.gov/?id=ED407420 [Accessed 10 Jun 2020]. Thompson FT , Levine DU . Examples of easily Explainable suppressor variables in multiple regression research. Multi Linear Regres Viewpoints 1997;24:11–13. “Stopping stepwise: Why stepwise selection is bad and what you should use instead”. On towardsdatascience.com. Available: https://towardsdatascience.com/stopping-stepwise-why-stepwise-selection-is-bad-and-what-you-should-use-instead-90818b3f52df [Accessed 10 Jun 2020]. Miñana B , Cózar JM , Palou J , et al . Bladder cancer in Spain 2011: population based study. J Urol 2014;191:323–8.doi:10.1016/j.juro.2013.08.049 http://www.ncbi.nlm.nih.gov/pubmed/23994371 Ciocan D , Barbe C , Aubin F , et al . Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol 2013;149:1150–7.doi:10.1001/jamadermatol.2013.706 http://www.ncbi.nlm.nih.gov/pubmed/23945633 Gridelli C , Balducci L , Ciardiello F , et al . Treatment of elderly patients with non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Clin Lung Cancer 2015;16:325–33.doi:10.1016/j.cllc.2015.02.006 http://www.ncbi.nlm.nih.gov/pubmed/25862554 Azawi NH , Joergensen SM , Jensen NV , et al . Trends in kidney cancer among the elderly in Denmark, 1980-2012. Acta Oncol 2016;55(Suppl 1):79–84.doi:10.3109/0284186X.2015.1115121 http://www.ncbi.nlm.nih.gov/pubmed/26784139 Wu T , Yang L , Jiang J , et al . Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats. Life Sci 2018;192:173–82.doi:10.1016/j.lfs.2017.11.049 http://www.ncbi.nlm.nih.gov/pubmed/29196049 He Z , Kong X , Shao T , et al . Alterations of the gut microbiota associated with promoting efficacy of prednisone by Bromofuranone in MRL/lpr mice. Front Microbiol 2019;10:978. doi:10.3389/fmicb.2019.00978 http://www.ncbi.nlm.nih.gov/pubmed/31118928 Li Z-Y , Fan M-B , Zhang S-L , et al . Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides. Acta Pharmacol Sin 2016;37:1458–66.doi:10.1038/aps.2016.70 http://www.ncbi.nlm.nih.gov/pubmed/27546006 Hagan T , Cortese M , Rouphael N , et al . Antibiotics-Driven gut microbiome perturbation alters immunity to vaccines in humans. Cell 2019;178:1313–28. e13.doi:10.1016/j.cell.2019.08.010 http://www.ncbi.nlm.nih.gov/pubmed/31491384 Bruno G , Zaccari P , Rocco G , et al . Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol 2019;25:2706–19.doi:10.3748/wjg.v25.i22.2706 http://www.ncbi.nlm.nih.gov/pubmed/31235994 Jackson MA , Goodrich JK , Maxan M-E , et al . Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016;65:749–56.doi:10.1136/gutjnl-2015-310861 http://www.ncbi.nlm.nih.gov/pubmed/26719299 Gao C , Major A , Rendon D , et al . Histamine H2 receptor-mediated suppression of intestinal inflammation by probiotic Lactobacillus reuteri. mBio 2015;6:e01358–15.doi:10.1128/mBio.01358-15 http://www.ncbi.nlm.nih.gov/pubmed/26670383 Diebel LN , Liberati DM , Hall-Zimmerman L . H2 blockers decrease gut mucus production and lead to barrier dysfunction in vitro. Surgery 2011;150:736–43.doi:10.1016/j.surg.2011.07.067 http://www.ncbi.nlm.nih.gov/pubmed/22000186 U.S. Food and Drug Administration . Questions and answers: NDMA impurities in ranitidine (commonly known as Zantac). Available: https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac [Accessed 14 Jun 2020]. European Medicines Agencies . EMA to review ranitidine medicines following detection of NDMA. Available: https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma [Accessed 14 Jun 2020]. Strobel L , Johswich KO . Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection. Sci Rep 2018;8:10225. doi:10.1038/s41598-018-28583-8 http://www.ncbi.nlm.nih.gov/pubmed/29977064 Taylor A . Revealing a brain-gut microbiome connection following chronic opioid treatment. J Pain 2018;19:S1.doi:10.1016/j.jpain.2017.12.012 Acharya C , Betrapally NS , Gillevet PM , et al . Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:319–31.doi:10.1111/apt.13858 http://www.ncbi.nlm.nih.gov/pubmed/27868217 Banerjee S , Sindberg G , Wang F , et al . Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol 2016;9:1418–28.doi:10.1038/mi.2016.9 http://www.ncbi.nlm.nih.gov/pubmed/26906406 Ren M , Lotfipour S . The role of the gut microbiome in opioid use. Behav Pharmacol 2020;31:113–21.doi:10.1097/FBP.0000000000000538 Dai X , Yan J , Fu X , et al . Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res 2017;23:6267–78.doi:10.1158/1078-0432.CCR-17-0242 http://www.ncbi.nlm.nih.gov/pubmed/28710312 Algra AM , Rothwell PM . Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518–27.doi:10.1016/S1470-2045(12)70112-2 http://www.ncbi.nlm.nih.gov/pubmed/22440112 Botti G , Fratangelo F , Cerrone M , et al . COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. J Transl Med 2017;15:46. doi:10.1186/s12967-017-1150-7 http://www.ncbi.nlm.nih.gov/pubmed/28231855 Zelenay S , van der Veen AG , Böttcher JP , et al . Cyclooxygenase-Dependent tumor growth through evasion of immunity. Cell 2015;162:1257–70.doi:10.1016/j.cell.2015.08.015 http://www.ncbi.nlm.nih.gov/pubmed/26343581 Ma X , Bi E , Lu Y , et al . Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. Cell Metab 2019;30:143–56. e5.doi:10.1016/j.cmet.2019.04.002 http://www.ncbi.nlm.nih.gov/pubmed/31031094 Yang W , Bai Y , Xiong Y , et al . Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 2016;531:651–5.doi:10.1038/nature17412 http://www.ncbi.nlm.nih.gov/pubmed/26982734 Mok EHK , Lee TKW . The pivotal role of the dysregulation of cholesterol homeostasis in cancer: implications for therapeutic targets. Cancers 2020;12:E1410. doi:10.3390/cancers12061410 http://www.ncbi.nlm.nih.gov/pubmed/32486083 Perrone F , Minari R , Bersanelli M , et al . The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors. J Immunother 2020;43:196–203.doi:10.1097/CJI.0000000000000321 http://www.ncbi.nlm.nih.gov/pubmed/32404654 De Giorgi V , Grazzini M , Benemei S , et al . Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol 2018;4:e172908. doi:10.1001/jamaoncol.2017.2908 http://www.ncbi.nlm.nih.gov/pubmed/28973254 Kokolus KM , Zhang Y , Sivik JM , et al . Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology 2018;7:e1405205. doi:10.1080/2162402X.2017.1405205 http://www.ncbi.nlm.nih.gov/pubmed/29399407 Thiele M , Wiest R , Gluud LL , et al . Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Med Hypotheses 2013;81:871–4.doi:10.1016/j.mehy.2013.08.026 http://www.ncbi.nlm.nih.gov/pubmed/24060485 Kichenadasse G , Miners JO , Mangoni AA , et al . Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol 2020;6:e195241:512. doi:10.1001/jamaoncol.2019.5241 http://www.ncbi.nlm.nih.gov/pubmed/31876896 Afzal MZ , Mercado RR , Shirai K . Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer 2018;6:64.doi:10.1186/s40425-018-0375-1 http://www.ncbi.nlm.nih.gov/pubmed/29966520 Coutinho AE , Chapman KE . The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011;335:2–13.doi:10.1016/j.mce.2010.04.005 http://www.ncbi.nlm.nih.gov/pubmed/20398732 Luo Y , Zheng SG . Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms. Front Immunol 2016;7:604. doi:10.3389/fimmu.2016.00604 http://www.ncbi.nlm.nih.gov/pubmed/28066415 Giles AJ , Hutchinson M-KND , Sonnemann HM , et al . Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 2018;6:51. doi:10.1186/s40425-018-0371-5 http://www.ncbi.nlm.nih.gov/pubmed/29891009 Biswas S , Benedict SH , Lynch SG , et al . Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Med 2012;10:57. doi:10.1186/1741-7015-10-57 http://www.ncbi.nlm.nih.gov/pubmed/22676575 Hussain M , Javeed A , Ashraf M , et al . Aspirin and immune system. Int Immunopharmacol 2012;12:10–20.doi:10.1016/j.intimp.2011.11.021 http://www.ncbi.nlm.nih.gov/pubmed/22172645